Introduction
Parainfluenza virus (PIV) is a type of paramyxovirus and is among the causal agents of common communityacquired respiratory infections with usually mild upper respiratory tract symptoms. In immunosuppressed patients, PIV-most commonly PIV-3-is able to cause more serious and even fatal infections, which occur mostly in patients with hematological malignancies (e.g. leukemia) or after hematopoietic stem cell or lung transplantation (1) (2) (3) (4) (5) .
Although PIV is able to cause serious life-threatening disease after lung or hematopoietic stem cell transplantation, limited data are available about the outcome and severity of PIV infections after kidney transplantation. The widespread use of readily available multiplex techniques with nucleic acid testing for several respiratory viruses simultaneously has made a specific microbiological diagnosis of respiratory tract infections feasible and rapid in the clinical setting, and this is very important, especially among immunosuppressed patients.
Our aim was to describe a recent outbreak of PIV-3 infections in a kidney transplant unit and to characterize the symptoms and outcome of PIV infections early after kidney or simultaneous pancreas-kidney (SPK) transplantation.
Materials and Methods
Approximately 240 kidney and 15-20 SPK transplantations are performed annually at our institution. Baseline immunosuppression is cyclosporine or tacrolimus, mycophenolate, and steroids. Induction with basiliximab is used in patients with higher immunological risk (retransplantation, poor HLA match, or immunized patients) and with anti-thymocyte globulin (ATG) in SPK patients. Tacrolimus and cyclosporine doses were adjusted according to trough levels. The target trough level after kidney transplantation for tacrolimus was 7-10 ng/mL during the first 3 mo and 4-6 ng/ mL thereafter, whereas the trough-level target for cyclosporine was 160-200 lg/L for the first 3 mo after transplantation, with tapering doses to a trough target of 80-110 lg/L at 1 year from transplantation. Mycophenolate was given 1000 mg twice a day with cyclosporine and 500 mg twice a day with tacrolimus. In SPK patients, the trough-level target for tacrolimus was 12-15 ng/mL during the first posttransplant month and 7-10 ng/mL thereafter. Helsinki is the only transplant center in Finland, and after kidney or SPK transplantation, patients remain hospitalized for approximately 10-21 days, after which they return to follow-up at their own district hospital. Due to renovations in the hospital area, the kidney transplant unit was relocated in a ward not designed for the treatment of immunosuppressed patients (16 patient beds). Patients were located two to three patients per small room, with shared sanitation in most rooms. In addition to early postoperative care, the surgical and immunological complications of most patients nationwide are treated on the transplant ward.
Respiratory viral infections were diagnosed with a qualitative multiplex polymerase chain reaction recognizing several common respiratory viruses from nasopharyngeal swabs. Nucleic acids extraction was performed using MagNa Pure (Roche Diagnostics, Basel, Switzerland), according to manufacturer's instructions, and the extracts were immediately subjected to the xTAG RVP FAST V2 assay (Luminex Molecular Diagnostics, Toronto, Canada), as described (6) . Tests were routinely taken from symptomatic patients, but after the onset of the outbreak, nasopharyngeal swab tests were taken from all exposed patients (i.e. sharing a room with an infected patient).
Pre-and posttransplant clinical and laboratory data were collected from patient files and the laboratory database. Estimated GFR was calculated using plasma creatinine and the Chronic Kidney Disease Epidemiology Collaboration equation (7). Difference in the distribution of continuous variables was assessed using the nonparametric Mann-Whitney U test. Relation between binary variables was calculated with the Fisher exact test. The calculations were performed with IBM SPSS statistics (version 21; IBM Corp, Armonk, NY). A p < 0.05 was considered significant.
Results
During the outbreak, 45 kidney or SPK recipients were treated on the ward. Respiratory viruses were tested in 29 patients (12 with upper or lower respiratory tract symptoms, 17 asymptomatic exposed patients). PIV-3 infection was confirmed in 12 patients, of which only one remained asymptomatic. In others, symptoms were mostly mild upper respiratory tract symptoms (rhinorrhea, nasal congestion, cough, fever, sore throat) and subsided spontaneously within a few days. In two patients, lower respiratory tract symptoms were present (dyspnea, hypoxemia, pulmonary infiltrates on chest computed tomography) and supplemental oxygen was required, but no intensive care unit admission or mechanical ventilation was needed. In these two patients, one of whom had received a kidney transplant and the other SPK transplantation, symptoms subsided completely without specific treatment within 12 and 5 days, respectively. Of note, four of six SPK patients were infected with PIV compared with eight of 39 kidney transplant patients (p = 0.04). No differences were seen in the severity of disease between kidney and SPK recipients. Patients with or without PIV-3 infections are compared in Table 1 . Patients with PIV-3 infections were more frequently on tacrolimus-based immunosuppression and had a longer duration of hospital stay; otherwise, no significant differences were observed. In addition, during the outbreak, one asymptomatic kidney transplant recipient was diagnosed with influenza A, and one SPK patient with mild upper respiratory tract symptoms was diagnosed with influenza B. Both patients had received a seasonal influenza vaccination during the previous the autumn and received treatment with oseltamivir after the diagnosis of influenza.
In all PIV-3-positive patients who had follow-up nasopharyngeal swab tests taken (n = 6), PIV-3 shedding was still detected 11-16 days after the first diagnosis. Followup samples were taken at 5-to 7-day intervals from patients who remained hospitalized, to define the need for continued isolation, or from patients who remained in follow-up in the transplant institution at the time of control visits at 2-to 4-week intervals. Two to six follow-up samples were taken per patient, and three patients were followed until negative. Follow-up samples were not associated with the severity of symptoms because all primary symptoms were mild and resolved rapidly. The majority of patients with PIV-3 infections (nine of 12) suffered from mild transient lymphopenia early after transplantation, but this was not associated with the severity of symptoms or the duration of PIV shedding (data not shown). Despite rapid diagnosis and isolation of symptomatic patients, positive PIV-3 findings were diagnosed within a period of 24 days. The outbreak ceased only after closing down the transplant ward temporarily.
One patient with PIV-3 infection after kidney transplantation died 2 mo after transplantation due to cardiac decompensation and severe bacterial pneumonia. In this patient, the graft was not functioning at the time of death. Other patients with PIV-3 infection were alive with functioning grafts, with mean estimated GFR of 61 AE 18 mL/min per 1.73 m 2 , at the end of follow-up (mean 12 AE 1 mo). One patient with no PIV-3 lost a graft due to venous thrombosis on the second postoperative day, but other grafts were functioning at the end of follow-up, a mean of 11 AE 3 mo after the outbreak.
Discussion
In the present study, we described a recent outbreak of PIV-3 infections in a kidney transplant unit and demonstrated that although PIV-3 very easily infected patients early after kidney or SPK transplantation, all infections were mild and symptoms resolved spontaneously rapidly. No primary mortality or need for mechanical ventilation was detected.
Although it is well known that PIV is able to cause serious disease in patients with hematological malignancies (e.g. leukemia) or after hematopoietic stem cell or lung transplantation (1-3) , not much data exist about PIV infections after kidney transplantation. To our knowledge, no previous case series of PIV infections after SPK transplantation has been described, and only one previous case report of a serious PIV infection after kidney transplantation in the recent era has been published (8) . In 1979, DeFabritius et al described an epidemic of PIV-3 infections in a renal transplantation service, during which 16 patients with recent renal transplantation were infected. Symptoms in all patients were mild upper respiratory tract symptoms, and PIV-3 infection was associated with increased frequency of acute rejections (9). In our current study, all patients presented with mild symptoms, and symptoms subsided rapidly without treatment, but no association with deterioration of graft function was observed. However, one patient with mild upper respiratory tract symptoms associated with PIV-3 infection died 68 days after the diagnosis of PIV-3 infection due to cardiac decompensation and bacterial pneumonia, and it is possible that the PIV infection might have predisposed this patient to a later fatal pneumonia. Similarly, PIV infections have been described as a risk factor for invasive aspergillosis (10), but in our cohort, no invasive fungal infections were detected before or after the outbreak.
In hematologic patients and lung transplant recipients, upper respiratory tract symptoms are the most common symptoms of PIV infections, but lower respiratory tract symptoms, mainly pneumonia, are seen in 13-37% of patients (1) (2) (3) 5, 11) , and mechanical ventilation is needed in %20% of patients (1, 11) . Mortality due to PIV infections is estimated to be %8-10% (1,2,11 ), but may be as high as 28-37% in patients with lower respiratory tract infection (3, 5, 12) . Successful treatment of PIV infection with intravenous or aerosolized ribavirin and intravenous immunoglobulin, or, more recently, with DAS181, has been reported (8, (13) (14) (15) (16) .
Outbreaks caused by PIV have been reported previously in hematopoietic stem cell transplant patients; PIV-3 has very easily infected immunosuppressed patients (17, 18) . Prolonged shedding of respiratory viruses, such as PIV, has been described in immunosuppressed transplant recipients (19) , highlighting the importance of infection control and preventive measures to adequately limit and control the outbreak. The outbreak in our transplant facility was similarly caused by PIV-3, and prolonged shedding of PIV-3 for 11-16 days was detected in all patients with follow-up samples available. Due to renovations, the kidney transplant ward at our institution was relocated to a facility not designed for immunosuppressed patients, and because of our recent experience with a serious outbreak of influenza A(H1N1) at our institution (20) , diagnosis and isolation of symptomatic patients in the present outbreak was rapid. Despite infectious control and preventive measures, the outbreak ceased after 24 days only after the temporary closure of the ward. Patients with PIV-3 infection had longer duration of hospital stay compared with patients without PIV-3 infection. The longer treatment time on the ward, however, was not due to the symptoms associated with PIV-3 but rather with other complications after transplantation, such as delayed graft function, urinary leakage, wound infection, or antibody-mediated rejection. Consequently, longer hospital stay and longer exposure on the ward were probably causes rather than consequences of PIV-3 infection.
In the current study, patients with PIV infection were more frequently on tacrolimus-based immunosuppression compared with patients without PIV infection, had more frequently received induction therapy, and had received a transplant <1 mo earlier-all factors associated with more intense immunosuppression, increasing the general risk for infections. In addition, patients with SPK transplantation were at significantly higher risk of PIV-3 infection compared with patients who received only kidney transplantation, also probably reflecting the more intense immunosuppression in SPK patients, who received ATG induction and had higher trough-level targets for tacrolimus compared with kidney transplant recipients. The small number of patients in our analysis did not allow us to perform multivariable models of the risk factors for PIV-3 infection. In addition, our study is limited by the lack of follow-up samples from some infected patients. On the other hand, our study is-to our knowledge-the largest case series in the current era of PIV infections after kidney or SPK transplantation and clearly demonstrates the relatively benign course of PIV infections, although the infections occurred very early after kidney or SPK transplantation.
In conclusion, PIV-3 infections early after kidney or SPK transplantation were mostly mild. PIV-3 easily infected immunosuppressed transplant recipients, especially more immunosuppressed patients who received SPK transplantation, and prolonged viral shedding was detected, highlighting the importance infection control measures in cases of outbreak.
